nimotuzumab
biocon,daiichi sankyo,oncoscience
['nimotuzumab', 'pancreatic']
nimotuzumab plus gemcitabine prolongs survival (median pfs 4.2 months vs. 3.6 months, median os 10.9 months vs. 8.5 months) in kras wild-type pancreatic cancer 
Professor of Medical Oncology,  Amrita Institute of Medical  Sciences. Oncologist and Hematologist